Quote from: Laura_7 on March 30, 2016, 01:28:28 PM
With sublingual intake the liver is bypassed, which lessens strain on the liver
Can you point to studies where bio-identical estradiol strains the liver?
Gynecol Endocrinol. 1993 Jun;7(2):111-4."Serum concentrations of sex hormone-binding globulin (SHBG), corticosteroid binding globulin (CBG), ceruloplasmin, lipoprotein A and liver enzymes were measured in 30 postmenopausal women treated with (...) micronized 17 beta-estradiol daily and micronized progesterone orally (...), as progestogen supplementation. The treatment lasted for 4 months. The serum levels of SHBG and CBG increased during treatment and a weak association between progesterone dosage and CBG was observed.
Levels of lipoprotein A and liver enzymes did not change. It is concluded that micronized natural progesterone is an attractive means of progesterone supplementation in postmenopausal hormone replacement therapy without any liver-related side-effects."
Exp Clin Endocrinol Diabetes. 2005 Dec;113(10):586-92." Sixty male-to-female transsexuals were treated with monthly injections of gonadotropin-releasing hormone agonist (GnRHa) and oral oestradiol-17beta valerate for 2 years to achieve feminisation until SRS."
"Liver enzymes, lipids, and prolactin levels were unchanged."Hepatol Res. 2007 Apr;37(4):239-47.
Protection of estrogens against the progression of chronic liver disease."Hepatic steatosis was reported to become evident in an aromatase-deficient mouse and was diminished in animals after treatment with estradiol. Our previous studies showed that
estradiol suppressed hepatic fibrosis in animal models, and attenuated HSC activation by suppressing the generation of reactive oxygen species in primary cultures."
Quoteand also blood clotting.
Journal of Clinical & Translational Endocrinology 2 (2015) 55-60"Other compelling data suggest that the incidence of venous thromboembolism (VTE) among transgender women appears associated with the presence of a hypercoaguable risk factor, including the use of an especially thrombogenic estrogen (ethinyl estradiol) which is no longer used [3]. Gooren et al. (2008), reported no increase in VTE among 2236 male-to-female (MTF) transgender individuals on HT from 1975 to 2006 compared with controls,
with the exception of those who used ethinyl estradiol, for which there was a 6-8% incidence [4]."
Menopause. 2006 Jul-Aug;13(4):643-50."Oral E(2), with or without NETA, produced no net activation of coagulation but improved fibrinolysis."
Fertil Steril. 1997 Sep;68(3):449-53.« Compared with placebo, oral E2 replacement therapy resulted in a significant decrease in fibrinogen and apo B and a significant increase in plasminogen."
Exp Clin Endocrinol Diabetes. 2005 Dec;113(10):586-92."
Sixty male-to-female transsexuals were treated with monthly injections of gonadotropin-releasing hormone agonist (GnRHa) and oral oestradiol-17beta valerate for 2 years to achieve feminisation until SRS."
"Two side effects were documented. One, venous thrombosis, occurred in a patient with a
homozygous MTHFR mutation."
Archives of Sexual Behavior, Vol. 27, No. 5, 1998"The incidence of thromboembolic events during cross-
gender hormone treatment in our patients was zero."
Despite moderate to high doses of oral bio-identical estradiol.
J Clin Endocrinol Metab. 2003 Dec;88(12):5723-9.
Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people."In conclusion, we have shown that treatment of MtF transsexuals with sex steroid hormones (CPA combined with E2 or EE) affects the hemostatic balance with a very pronounced difference in the effects of oral EE compared with the effects of both td E2 or oral E2. Oral EE induces a clinically relevant prothrombotic state."
Aust N Z J Obstet Gynaecol. 1978 Aug;18(3):198-201."The effect of oestradiol valerate on levels of blood cholesterol, triglycerides, free oestradiol and coagulation factors, as well as on urinary oestrogens and free cortisol was measured in 10 oöphorectomised women. Despite the very high urinary oestrogen levles obtained, there was no significant change found in the other parameters during and after treatment. These findings are discussed, as is the significance of the metabolism of both endogenously produced and orally administered oestrogens in the menopausal woman."
J Thromb Haemost. 2014 Mar 15."The hemostatic profile of women using CEE is more prothrombotic than that of women using E2. These findings provide further evidence for a different thrombotic risk for oral CEE and oral E2."
Minerva Med. 2013 Apr;104(2):161-7."Estradiol itself has a lower impact on estrogen-hepatic proteins, and is more readily metabolized by the liver than ethinyl estradiol, the ethinyl group on which slows down that process. The structure increases the bioavailability of ethinyl estradiol compared with E2, but may also contribute to an increased likelihood of estrogen-related adverse events.40 »
Minerva Ginecol. 2014 Feb;66(1):91-102."Micronized estradiol (E2) and its estere valerate (EV), is more easily metabolized by the liver than ethynylestradiol (EE). This causes minimal metabolic impact »
"In comparison to EE/levonorgestrel (LNG), EV/DNG is more neutral on metabolism and coagulation"
"E2/NOMAc is more neutral than EE/LNG on metabolism and more neutral than EE/DRSP on coagulation"
QuoteIts also more effective since the liver breaks down part of it.
Sublingually, there is still some estradiol that inevitably gets swallowed. And quick peaks and valleys may cause neurological symptoms. I found no difference between either route in terms of effects on feminization, breast growth or well-being. Sublingual can be inconvenient and a pain in the a?&. Orally, it's easier.
QuoteIf there is estrogen in the digestive tract the liver presumes a leak and raises clotting factors.
The reason clotting factors and proteins get modified is due to the triggering of estrogen receptors in the portal vein, from the intestines to the liver.